Other Species / Isoforms
  AP-2 alpha (human)      LTP 

LTP (Low Throughput Papers) : The number of records in which this modification site was determined using methods other than discovery mass spectrometry.

  HTP 

HTP (High Throughput Papers): The number of records in which this modification site was assigned using ONLY proteomic discovery mass spectrometry.

 
K10-sm
WKLTDNIkYEDCEDR
Upstream
Downstream
1 2
Effects on Modified Protein
  • activity, induced
Effects on Biological Processes:
  • transcription, induced
Treatment
  • hypoxia
AP-2 alpha (human) WKLTDNIkYEDCEDR K10-sm
AP-2 alpha iso2 (human) gap -
AP-2 alpha (mouse) WKLTDNIKYEDCEDR K10
AP-2 alpha (rat) gap -
K10-ub
WKLTDNIkYEDCEDR
0 1
AP-2 alpha (human) WKLTDNIkYEDCEDR K10-ub
AP-2 alpha iso2 (human) gap -
AP-2 alpha (mouse) WKLTDNIKYEDCEDR K10
AP-2 alpha (rat) gap -
Y73-p
YPQSQDPySHVNDPY
0 1
AP-2 alpha (human) YPQSQDPySHVNDPY Y73-p
AP-2 alpha iso2 (human) YPQSQDPYSHVNDPY Y67
AP-2 alpha (mouse) YPQSQDPYSHVNDPY Y73
AP-2 alpha (rat) YPQSQDPYSHVNDPY Y73
S119-p
RGLPHQLsGLDPRRD
0 2
AP-2 alpha (human) RGLPHQLsGLDPRRD S119-p
AP-2 alpha iso2 (human) RGLPHQLSGLDPRRD S113
AP-2 alpha (mouse) RGLPHQLsGLDPRRD S119-p
AP-2 alpha (rat) RGLPHQLSGLDPRRD S119
K177-sm
PDQTVIKkGPVsLSk
0 1
AP-2 alpha (human) PDQTVIKkGPVsLSk K177-sm
AP-2 alpha iso2 (human) PDQTVIKKGPVSLSK K171
AP-2 alpha (mouse) PDQTVIKKGPVSLSK K177
AP-2 alpha (rat) PDQTVIKKGPVSLSK K177
K177-ub
PDQTVIKkGPVsLSk
0 1
AP-2 alpha (human) PDQTVIKkGPVsLSk K177-ub
AP-2 alpha iso2 (human) PDQTVIKKGPVSLSK K171
AP-2 alpha (mouse) PDQTVIKKGPVSLSK K177
AP-2 alpha (rat) PDQTVIKKGPVSLSK K177
S181-p
VIKkGPVsLSksNsN
0 1
AP-2 alpha (human) VIKkGPVsLSksNsN S181-p
AP-2 alpha iso2 (human) VIKKGPVSLSKSNSN S175
AP-2 alpha (mouse) VIKKGPVSLSKSNsN S181
AP-2 alpha (rat) VIKKGPVSLSKSNSN S181
K184-ub
kGPVsLSksNsNAVS
0 1
AP-2 alpha (human) kGPVsLSksNsNAVS K184-ub
AP-2 alpha iso2 (human) KGPVSLSKSNSNAVS K178
AP-2 alpha (mouse) KGPVSLSKSNsNAVS K184
AP-2 alpha (rat) KGPVSLSKSNSNAVS K184
S185-p
GPVsLSksNsNAVSA
0 1
AP-2 alpha (human) GPVsLSksNsNAVSA S185-p
AP-2 alpha iso2 (human) GPVSLSKSNSNAVSA S179
AP-2 alpha (mouse) GPVSLSKSNsNAVSA S185
AP-2 alpha (rat) GPVSLSKSNSNAVSA S185
S187-p
VsLSksNsNAVSAIP
Upstream
0 5
Treatment
  • ischemia
AP-2 alpha (human) VsLSksNsNAVSAIP S187-p
AP-2 alpha iso2 (human) VSLSKSNSNAVSAIP S181
AP-2 alpha (mouse) VSLSKSNsNAVSAIP S187-p
AP-2 alpha (rat) VSLSKSNSNAVSAIP S187
K197-ub
VSAIPINkDNLFGGV
0 1
AP-2 alpha (human) VSAIPINkDNLFGGV K197-ub
AP-2 alpha iso2 (human) VSAIPINKDNLFGGV K191
AP-2 alpha (mouse) VSAIPINKDNLFGGV K197
AP-2 alpha (rat) VSAIPINKDNLFGGV K197
S219-p
CSVPGRLsLLSSTSK
Upstream
Downstream
3 0
Effects on Modified Protein
  • activity, induced
  • molecular association, regulation
Effects on Biological Processes:
  • transcription, induced
Kinase, in vitro:
  • AMPKA2 (human)
Putative in vivo kinases:
  • AMPKA2 (human)
Treatment
  • angiotensin_2
  • aspirin
  • compound_C
  • nicotine
  • siRNA
view more >
AP-2 alpha (human) CSVPGRLsLLSSTSK S219-p
AP-2 alpha iso2 (human) CSVPGRLSLLSSTSK S213
AP-2 alpha (mouse) CSVPGRLsLLSSTSK S219-p
AP-2 alpha (rat) CSVPGRLSLLSSTSK S219
S239-p
AEVQRRLsPPECLNA
Upstream
1 6
Kinase, in vitro:
  • PKACA (human)
Putative in vivo kinases:
  • PKACA (human)
AP-2 alpha (human) AEVQRRLsPPECLNA S239-p
AP-2 alpha iso2 (human) AEVQRRLSPPECLNA S233
AP-2 alpha (mouse) AEVQRRLsPPECLNA S239-p
AP-2 alpha (rat) AEVQRRLSSPECLNA S239
S258-p
GVLRRAKsKNGGRSL
Upstream
Downstream
2 0
Effects on Modified Protein
  • molecular association, regulation
Effects on Biological Processes:
  • transcription, altered
Kinase, in vitro:
  • PRKD1 (human)
AP-2 alpha (human) GVLRRAKsKNGGRSL S258-p
AP-2 alpha iso2 (human) GVLRRAKSKNGGRSL S252
AP-2 alpha (mouse) GVLRRAKsKNGGrSL S258-p
AP-2 alpha (rat) GVLRRAKSKNGGRSL S258
R263
AKsKNGGRSLREKLD
0 1
AP-2 alpha (human) AKsKNGGRSLREKLD R263
AP-2 alpha iso2 (human) AKSKNGGRSLREKLD R257
AP-2 alpha (mouse) AKsKNGGrSLREKLD R263-m1
AP-2 alpha (rat) AKSKNGGRSLREKLD R263
K315-ub
CETEFPAkAVAEFLN
0 1
AP-2 alpha (human) CETEFPAkAVAEFLN K315-ub
AP-2 alpha iso2 (human) CETEFPAKAVAEFLN K309
AP-2 alpha (mouse) CETEFPAKAVAEFLN K315
AP-2 alpha (rat) CETEFPAKAVAEFLN K315
S326-p
EFLNRQHsDPNEQVT
Upstream
1 0
Kinase, in vitro:
  • PRKD1 (human)
AP-2 alpha (human) EFLNRQHsDPNEQVT S326-p
AP-2 alpha iso2 (human) EFLNRQHSDPNEQVT S320
AP-2 alpha (mouse) EFLNRQHSDPNEQVA S326
AP-2 alpha (rat) EFLNRQHSDPNEQVA S326
K411-ub
EALKAMDkMYLSNNP
0 1
AP-2 alpha (human) EALKAMDkMYLSNNP K411-ub
AP-2 alpha iso2 (human) EALKAMDKMYLSNNP K405
AP-2 alpha (mouse) EALKAMDKMYLSNNP K411
AP-2 alpha (rat) EALKAMDKMYLSNNP K411
S428-p
HTDNNAKssDKEEKH
0 1
AP-2 alpha (human) HTDNNAKssDKEEKH S428-p
AP-2 alpha iso2 (human) HTDNNAKSSDKEEKH S422
AP-2 alpha (mouse) HTDNSAKSSDKEEKH S428
AP-2 alpha (rat) HTDNSAKSSDKEEKH S428
S429-p
TDNNAKssDKEEKHR
Upstream
Downstream
1 0
Effects on Modified Protein
  • protein stabilization
Effects on Biological Processes:
  • transcription, induced
Kinase, in vitro:
  • CK2A1 (human)
Putative in vivo kinases:
  • CK2A1 (human)
AP-2 alpha (human) TDNNAKssDKEEKHR S429-p
AP-2 alpha iso2 (human) TDNNAKSSDKEEKHR S423
AP-2 alpha (mouse) TDNSAKSSDKEEKHR S429
AP-2 alpha (rat) TDNSAKSSDKEEKHR S429